Pharmaceutical company Pril's injection drug Carfizomib has been approved for domestic marketing.

Pfizer Pharmaceuticals recently received the injection of carfilzomib drug registration certificate issued by the National Medical Products Administration, which is equivalent to passing the evaluation of generic drug quality and efficacy consistency, and officially approved for marketing. This product is a potent anti-tumor drug for the treatment of relapsed/refractory multiple myeloma.